Top 10 Trends in Medicine, September 2014

Ryan Syrek


September 23, 2014

#5 Clinical Trend: Pembrolizumab

Recently approved by the US Food and Drug Administration (FDA), pembrolizumab is the first immunomodulator that acts as a programmed death inhibitor. It has been approved for use in patients with advanced or unresectable melanoma who are not responding to other medications.

For more in-depth clinical information, see Pembrolizumab.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.